Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($) $ in Millions |
12 Months Ended | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | $ 1,863 | $ 1,824 | $ 2,113 | ||||||||||||||||||||||
| Cost of sales | 1,262 | 1,275 | 1,495 | ||||||||||||||||||||||
| Selling, general and administrative expense | 377 | 344 | 404 | ||||||||||||||||||||||
| Research and development expense | 55 | 54 | 55 | ||||||||||||||||||||||
| Equity and other income | 4 | 4 | 6 | ||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 8 | 867 | 115 | ||||||||||||||||||||||
| Operating income (loss) | 105 | (775) | (26) | ||||||||||||||||||||||
| Net interest and other expense (income) | 40 | 33 | (24) | ||||||||||||||||||||||
| Other net periodic benefit (income) loss | (4) | 1 | 22 | ||||||||||||||||||||||
| Income (loss) from continuing operations before income taxes | 69 | (809) | (24) | ||||||||||||||||||||||
| EBITDA | [1] | 290 | (538) | 248 | |||||||||||||||||||||
| Depreciation expense | [2] | 125 | 174 | 198 | |||||||||||||||||||||
| Amortization expense | 60 | 63 | 76 | ||||||||||||||||||||||
| Additions to property, plant and equipment | 88 | 98 | 137 | ||||||||||||||||||||||
| Assets | 4,527 | 4,611 | |||||||||||||||||||||||
| Property, plant and equipment, net | 1,134 | 1,201 | |||||||||||||||||||||||
| Operating Segments [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Selling, general and administrative expense | 260 | 232 | 252 | ||||||||||||||||||||||
| Research and development expense | 51 | 52 | 52 | ||||||||||||||||||||||
| Equity and other income | 1 | 1 | 0 | ||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 0 | 706 | 0 | ||||||||||||||||||||||
| Operating income (loss) | 231 | (502) | 238 | ||||||||||||||||||||||
| EBITDA | [1] | 415 | (265) | 512 | |||||||||||||||||||||
| Depreciation expense | 124 | 174 | 198 | ||||||||||||||||||||||
| Intersegment Eliminations [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | [3] | (39) | (42) | (47) | |||||||||||||||||||||
| Cost of sales | (39) | (42) | (47) | ||||||||||||||||||||||
| Life Sciences [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 671 | 641 | 810 | ||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 0 | 375 | 0 | ||||||||||||||||||||||
| Amortization expense | 18 | 18 | 23 | ||||||||||||||||||||||
| Additions to property, plant and equipment | 31 | 49 | 61 | ||||||||||||||||||||||
| Assets | 1,422 | 1,498 | |||||||||||||||||||||||
| Property, plant and equipment, net | 440 | 481 | |||||||||||||||||||||||
| Life Sciences [Member] | Operating Segments [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 671 | 641 | 810 | ||||||||||||||||||||||
| Cost of sales | 411 | 418 | 515 | ||||||||||||||||||||||
| Selling, general and administrative expense | 97 | 77 | 89 | ||||||||||||||||||||||
| Research and development expense | 14 | 15 | 15 | ||||||||||||||||||||||
| Equity and other income | 0 | 0 | 0 | ||||||||||||||||||||||
| Operating income (loss) | [4] | 131 | (262) | 168 | |||||||||||||||||||||
| EBITDA | [1] | 187 | (187) | 229 | |||||||||||||||||||||
| Depreciation expense | [5] | 38 | 57 | 38 | |||||||||||||||||||||
| Personal Care [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 0 | 0 | 0 | ||||||||||||||||||||||
| Amortization expense | 32 | 35 | 43 | ||||||||||||||||||||||
| Additions to property, plant and equipment | 9 | 7 | 11 | ||||||||||||||||||||||
| Assets | 701 | 751 | |||||||||||||||||||||||
| Property, plant and equipment, net | 106 | 101 | |||||||||||||||||||||||
| Personal Care [Member] | Operating Segments [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 592 | 577 | 634 | ||||||||||||||||||||||
| Cost of sales | 350 | 345 | 398 | ||||||||||||||||||||||
| Selling, general and administrative expense | 87 | 84 | 95 | ||||||||||||||||||||||
| Research and development expense | 23 | 25 | 26 | ||||||||||||||||||||||
| Equity and other income | 1 | 1 | 0 | ||||||||||||||||||||||
| Operating income (loss) | [6] | 101 | 90 | 73 | |||||||||||||||||||||
| EBITDA | [1] | 161 | 155 | 152 | |||||||||||||||||||||
| Depreciation expense | [7] | 28 | 30 | 36 | |||||||||||||||||||||
| Specialty Additives [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 504 | 511 | 572 | ||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 0 | 331 | 0 | ||||||||||||||||||||||
| Amortization expense | 9 | 9 | 10 | ||||||||||||||||||||||
| Additions to property, plant and equipment | 42 | 34 | 61 | ||||||||||||||||||||||
| Assets | 964 | 1,020 | |||||||||||||||||||||||
| Property, plant and equipment, net | 463 | 484 | |||||||||||||||||||||||
| Specialty Additives [Member] | Operating Segments [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 504 | 511 | 572 | ||||||||||||||||||||||
| Cost of sales | 423 | 433 | 522 | ||||||||||||||||||||||
| Selling, general and administrative expense | 70 | 64 | 61 | ||||||||||||||||||||||
| Research and development expense | 14 | 12 | 11 | ||||||||||||||||||||||
| Equity and other income | 0 | 0 | 0 | ||||||||||||||||||||||
| Operating income (loss) | [8] | (12) | (338) | (32) | |||||||||||||||||||||
| EBITDA | [1] | 51 | (254) | 89 | |||||||||||||||||||||
| Depreciation expense | [9] | 54 | 75 | 111 | |||||||||||||||||||||
| Intermediates [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 0 | 0 | 0 | ||||||||||||||||||||||
| Amortization expense | 1 | 1 | 0 | ||||||||||||||||||||||
| Additions to property, plant and equipment | 4 | 3 | 2 | ||||||||||||||||||||||
| Assets | 116 | 116 | |||||||||||||||||||||||
| Property, plant and equipment, net | 31 | 30 | |||||||||||||||||||||||
| Intermediates [Member] | Operating Segments [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Sales | 135 | 137 | 144 | ||||||||||||||||||||||
| Cost of sales | 117 | 121 | 107 | ||||||||||||||||||||||
| Selling, general and administrative expense | 6 | 7 | 7 | ||||||||||||||||||||||
| Research and development expense | 0 | 0 | 0 | ||||||||||||||||||||||
| Equity and other income | 0 | 0 | 0 | ||||||||||||||||||||||
| Operating income (loss) | 11 | 8 | 29 | ||||||||||||||||||||||
| EBITDA | [1] | 16 | 21 | 42 | |||||||||||||||||||||
| Depreciation expense | 4 | 12 | 13 | ||||||||||||||||||||||
| Unallocated and Other [Member] | |||||||||||||||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||||||||||||||
| Selling, general and administrative expense | 117 | 112 | 152 | ||||||||||||||||||||||
| Research and development expense | 4 | 2 | 3 | ||||||||||||||||||||||
| Equity and other income | 3 | 3 | 6 | ||||||||||||||||||||||
| Goodwill impairment and loss on divestitures, net | 8 | 161 | 115 | ||||||||||||||||||||||
| Operating income (loss) | [10] | (126) | (273) | (264) | |||||||||||||||||||||
| EBITDA | [1] | (125) | (273) | (264) | |||||||||||||||||||||
| Depreciation expense | [11] | 1 | 0 | 0 | |||||||||||||||||||||
| Additions to property, plant and equipment | 2 | 5 | $ 2 | ||||||||||||||||||||||
| Assets | 1,324 | 1,226 | |||||||||||||||||||||||
| Property, plant and equipment, net | $ 94 | $ 105 | |||||||||||||||||||||||
| |||||||||||||||||||||||||
| X | ||||||||||
- Definition Earnings before interest, tax, depreciation and amortization. No definition available.
|
| X | ||||||||||
- Definition Goodwill impairment and (income) loss on acquisitions and divestitutres, net. No definition available.
|
| X | ||||||||||
- Definition Income (loss) from equity method investments and other income (expense). No definition available.
|
| X | ||||||||||
- Definition Other defined benefit plan net periodic benefit income expense. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset recognized for present right to economic benefit. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as operating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expenditure for addition to long-lived asset included in determination of segment asset by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Long-lived asset excludes financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|